"The GBM investigational pipeline in 2025–2026 is characterized by mechanistic breadth and increasing biological sophistication."
BUFFALO, NY — September 25, 2026 — A new research perspective was published in Volume 13 of Oncoscience on September 17, 2026, titled " Emerging pharmacological agents for glioblastoma multiforme: An update on active clinical trials (2025–2026) ."
The article reviews emerging treatments being investigated for glioblastoma multiforme (GBM), including agents in active and recently completed clinical trials. GBM is an aggressive primary brain tumor in adults with a median overall survival of approximately 15 months despite surgery, radiotherapy and temozolomide. The authors organize the evolving treatment landscape into four major areas: molecular-targeted therapies, immunotherapies and vaccines, oncolytic viruses and gene therapies, and agents targeting tumor metabolism and the microenvironment.
The perspective was led by first and corresponding author Mamunur Rahman from the Department of Pharmacy, East West University, Aftabnagar, Dhaka, Bangladesh .
GBM remains particularly difficult to treat because of several biological barriers. Tumors can contain genetically and functionally diverse cancer-cell populations, while an immunosuppressive tumor microenvironment limits effective antitumor immune responses. The blood-brain barrier further restricts the ability of many systemically administered drugs to reach therapeutic concentrations within the tumor. Hypoxia and other features of the tumor environment can also promote treatment resistance.
One major direction is molecularly targeted therapy. The review discusses molecularly targeted approaches involving B7-H3, CDK4/6, the RAS/MAPK pathway, BRAF alterations and other molecular vulnerabilities. Abemaciclib, a CDK4/6 inhibitor with relatively favorable brain penetration, is being investigated in combination with the ERK inhibitor LY3214996. Regorafenib, which inhibits multiple kinases involved in angiogenic and proliferative signaling, previously improved median overall survival compared with lomustine in the Phase 2 REGOMA trial for recurrent GBM, although it was also associated with more severe adverse events.
The review also highlights the growing importance of biomarker-guided patient selection. Molecular characteristics such as MGMT promoter methylation, IDH mutation status, EGFR amplification and BRAF V600E can help define biologically distinct patient groups and guide enrollment in trials evaluating particular therapeutic strategies. This reflects a broader movement away from treating GBM as a single uniform disease and toward matching treatments with molecular features of individual tumors.
Immunotherapy represents another major area of investigation. Dendritic cell vaccines are designed to expose the immune system to tumor-associated antigens and generate cytotoxic T-cell responses. The review discusses DCVax-L and other vaccine approaches, including the plasmid DNA vaccines INO-5401 and INO-9012 in combination with the PD-1 inhibitor cemiplimab. These strategies aim to generate immune responses against multiple tumor antigens while counteracting the profound immune suppression characteristic of GBM.
CAR T-cell therapy is also being adapted to address the molecular heterogeneity of glioblastoma. Because tumor cells can lose individual target antigens, investigators are developing bivalent and multivalent CAR constructs capable of recognizing more than one tumor-associated antigen. The perspective discusses a bivalent CAR T-cell strategy targeting EGFR and IL-13Rα2 in recurrent GBM, as well as engineered tumor-infiltrating lymphocytes designed to produce anti-PD-1 antibodies within tumors. Challenges include antigen loss, T-cell exhaustion, neurotoxicity, delivery route and the immunosuppressive tumor microenvironment.
Beyond targeted drugs and immunotherapy, investigators are exploring oncolytic and gene-therapy platforms. Retroviral replicating vectors such as DB107-RRV/DB107-FC are designed to spread selectively through dividing tumor cells and convert a prodrug into a cytotoxic compound within the tumor. Other experimental gene-therapy approaches seek to combine tumor-selective activity with immune stimulation. These strategies remain investigational and face challenges involving delivery, antiviral immunity and the specialized infrastructure required for treatment.
GBM's altered metabolism provides another therapeutic target. The review describes agents such as BPM31510, which targets mitochondrial bioenergetics and redox homeostasis, and ASC40, an inhibitor of fatty acid synthase. Both are being evaluated in clinical trials, reflecting growing interest in disrupting the metabolic flexibility that allows GBM cells to survive under hypoxic and nutrient-limited conditions.
Despite this expanding pipeline, the authors emphasize that major barriers remain. Intratumoral heterogeneity can allow resistant cell populations to escape single-target treatments. Immunotherapies must overcome suppressive macrophages, myeloid-derived suppressor cells, regulatory T cells and chronic T-cell exhaustion. Systemic agents must cross the blood-brain barrier, while tumor cells can adapt their metabolism in response to therapeutic pressure. Differences among clinical trials in eligibility criteria, endpoints, imaging assessments and corticosteroid use also complicate comparisons between treatments.
Importantly, none of the emerging approaches reviewed has replaced the current temozolomide-based treatment paradigm. Instead, the evolving strategy is increasingly centered on biomarker-directed combinations, in which targeted, immune-based or metabolic treatments are added for molecularly defined groups of patients.
"The combination of precision molecular targeting with new immune activation methods and CNS-based drug delivery and metabolic interference establishes a foundation for developing combination therapies which should use proven predictive biomarkers for maximum effectiveness."
Future progress may depend on adaptive clinical trial platforms that evaluate multiple therapies and molecular subgroups simultaneously, rational combinations that target several aspects of GBM biology, personalized neoantigen vaccines and improved methods for delivering therapies across the blood-brain barrier. The authors also highlight emerging liquid-biopsy and imaging biomarkers as potential tools for assessing treatment response.
Overall, the perspective describes a GBM treatment landscape moving from broadly applied cytotoxic approaches toward mechanism-based, biomarker-guided and combination strategies. Molecular targeting, immune activation, gene and oncolytic therapies, metabolic interventions and improved CNS drug delivery are being investigated in parallel, but substantial biological and clinical obstacles remain. Results from ongoing Phase II and III studies will be critical for determining which approaches ultimately advance toward regulatory consideration.
DOI: https://doi.org/10.18632/oncoscience.671
